Healthcare / Medical Instruments & SuppliesIOB
$1.61
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $34.5M · quality 55.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$767M
P/E
53.8x
↑EV/EBITDA
6.5x
↓ROE
12.4%
↑Gross Margin
60.9%
↑Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.0%
FCF CAGR
—
FCF margin
8.0%
FCF / Net income
1.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $983.4M · net income $48.6M · FCF $78.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $983.4M | $983.4M | $993.2M | $1.02B | $1.08B |
| Net Income | $48.6M | $48.6M | $22.3M | $-24.6M | $54.2M |
| EBITDA | $111.7M | $111.7M | $82.4M | $47.5M | $120.9M |
| EPS | 0.12 | 0.12 | 0.05 | -0.06 | 0.13 |
| Gross Margin | 60.9% | 60.9% | 59.7% | 57.2% | 55.5% |
| Operating Margin | 4.8% | 4.8% | 2.9% | -0.3% | 3.5% |
| Net Margin | 4.9% | 4.9% | 2.2% | -2.4% | 5.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.31 | 0.42 | 0.47 |
| Current Ratio | 1.94 | 1.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $78.8M | $78.8M | $27.5M | $34.5M | $-6.7M |
| Returns | |||||
| ROE | 12.4% | 12.4% | 5.4% | -6.5% | 13.2% |
| Valuation | |||||
| P/E | 53.83 | 53.83 | 17.25 | — | 12.14 |
| EV/EBITDA | 6.47 | 6.47 | 5.67 | 9.48 | 6.39 |
| P/B | 1.73 | 1.73 | 0.93 | 0.97 | 1.61 |
| Growth & Yield | |||||
| Revenue Growth | -1.0% | -1.0% | -3.1% | -4.8% | — |
| EPS Growth | 114.8% | 114.8% | 190.0% | -146.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
7.3%
EPS terminal req.
$0.14
Spread vs growth
107.5%
5Y implied EPS CAGR
8.4%
EPS terminal req.
$0.17
Spread vs growth
106.4%
10Y implied EPS CAGR
9.2%
EPS terminal req.
$0.28
Spread vs growth
105.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+88.5%
Start / end P/E
15.8x → 13.9x
EPS bridge
0.05 → 0.12
Residual
-14.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.